Umbrales para iniciar inhibidores de SGLT2 en ERC no diabética

Respuesta generada por Itaca · 43 fuentes · 29 de noviembre de 2025

Pregunta original

Umbrales de Filtrado Glomerular y Albuminuria para Iniciar Tratamiento con Inhibidores de SGLT2 en Enfermedad Renal Crónica no Asociada a Diabetes

Clinical Thresholds for Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Non-Diabetic Chronic Kidney Disease: Evidence-Based Filtration Rate and Albuminuria Criteria

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have fundamentally transformed the therapeutic landscape for chronic kidney disease, emerging as a cornerstone intervention that effectively delays disease progression regardless of diabetic status. The clinical determination of appropriate initiation thresholds for estimated glomerular filtration rate and albuminuria in non-diabetic chronic kidney disease represents a critical juncture in clinical decision-making, where evolving evidence has substantially expanded treatment eligibility beyond the initial diabetic populations studied in early trials. Current evidence supports SGLT2 inhibitor initiation in non-diabetic patients with estimated glomerular filtration rate as low as 20 mL/min per 1.73 m² and across the full spectrum of albuminuria levels, from normoalbuminuria to nephrotic-range proteinuria, with the magnitude of renal protection demonstrating remarkable consistency across these diverse clinical presentations. This comprehensive analysis synthesizes contemporary trial evidence, guideline recommendations, and real-world effectiveness data to establish the evidence basis for these critical threshold decisions in non-diabetic chronic kidney disease management.

Epidemiological Context and Clinical Significance of Non-Diabetic Chronic Kidney Disease

Non-diabetic chronic kidney disease constitutes a substantial and clinically significant portion of the overall chronic kidney disease burden encountered in contemporary clinical practice, representing a heterogeneous group of pathological entities that diverge fundamentally from the glucose metabolism dysfunction central to diabetic nephropathy.[1][2] The causes of non-diabetic chronic kidney disease are remarkably diverse, encompassing primary glomerular diseases such as immunoglobulin A nephropathy and focal segmental glomerulosclerosis, secondary glomerular disorders including lupus nephritis and ANCA-associated vasculitis, hypertensive kidney disease, ischemic nephropathy, tubulointerstitial diseases, and genetic forms of kidney disease including Alport syndrome and autosomal dominant polycystic kidney disease. The complexity of non-diabetic chronic kidney disease pathophysiology extends beyond the characteristic glomerular hyperfiltration and sodium retention mechanisms that dominate diabetic kidney disease, incorporating immune-mediated inflammation, genetic dysregulation of glomerular structure and function, and tubular dysfunction through diverse mechanistic pathways.[1][3] The clinical importance of establishing evidence-based initiation thresholds for SGLT2 inhibitors in this population becomes particularly apparent when considering that many non-diabetic chronic kidney disease subtypes disproportionately affect younger patients, potentially warranting decades of disease modification to prevent progression to end-stage renal disease. Furthermore, traditional therapeutic options for non-diabetic chronic kidney disease have been limited primarily to renin-angiotensin system blockade, with immunosuppressive therapy reserved for specific etiologies and carrying significant adverse effect profiles, underscoring the clinical imperative to establish the appropriate role of SGLT2 inhibitors across this heterogeneous population.

Evolution of Evidence: From Diabetic to Non-Diabetic Chronic Kidney Disease Indications

The historical trajectory of SGLT2 inhibitor development and clinical validation illustrates a progressive expansion of therapeutic applications from their initial indication in type 2 diabetes mellitus to increasingly broader populations with chronic kidney disease and heart failure. Early landmark trials including EMPA-REG OUTCOME, CANVAS Program, and DECLARE-TIMI 58 were conducted primarily in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease or high cardiovascular risk, enrolling relatively small numbers of non-diabetic participants or requiring diabetes as an inclusion criterion.[4] These trials, although not powered specifically for renal outcomes, demonstrated secondary renal benefits that catalyzed interest in evaluating SGLT2 inhibitors more systematically in non-diabetic populations. The CREDENCE trial represented a critical intermediate step, enrolling 4401 participants with type 2 diabetes and chronic kidney disease (eGFR 30 to less than 90 mL/min per 1.73 m²) and demonstrating that canagliflozin reduced the composite renal outcome of kidney failure and persistent eGFR reduction, with subsequent subgroup analyses revealing comparable benefits in the smaller non-diabetic subgroup.[2] However, the transformative evidence for non-diabetic chronic kidney disease emerged with the DAPA-CKD trial, which revolutionized clinical perspectives by randomizing 4304 participants with chronic kidney disease (25 to 75% with eGFR, and urinary albumin-to-creatinine ratio 200 to 5000 mg/g) to dapagliflozin 10 mg daily or placebo on background renin-angiotensin system blockade, with the remarkable finding that 32.4% of participants had no diabetes mellitus at baseline.[1][2] The DAPA-CKD trial demonstrated that dapagliflozin was equally effective in non-diabetic patients as in diabetic patients, with a hazard ratio of 0.50 (95% confidence interval 0.35 to 0.72) for the primary composite outcome in non-diabetic participants, establishing definitively that SGLT2 inhibitor-mediated renal protection extends beyond glucose-related mechanisms.[1][2]

The EMPA-KIDNEY trial, completed more recently, substantially advanced evidence by enrolling 6609 participants with chronic kidney disease on background renin-angiotensin system blockade, deliberately incorporating higher proportions of non-diabetic participants (54% had no prior history of diabetes mellitus at recruitment), and crucially employing wider eligibility criteria that enrolled patients with eGFR as low as 20 mL/min per 1.73 m² and incorporating substantial numbers of patients with lower albuminuria levels.[5][6][2] Notably, EMPA-KIDNEY enrolled 48.3% of participants with urinary albumin-to-creatinine ratio less than 300 mg/g, including 1328 patients who were completely normoalbuminuric, addressing a critical evidence gap that prior trials had not adequately investigated.[1][2] The trial enrolled larger representation of multiple non-diabetic kidney disease causes, including greater than 1600 participants with glomerular disease, greater than 1400 with hypertensive kidney disease, greater than 450 with tubulointerstitial disease, and greater than 600 with unknown cause.[5] The EMPA-KIDNEY trial confirmed and substantially expanded the findings from DAPA-CKD, demonstrating that empagliflozin reduced the risk of the composite primary outcome of kidney disease progression or cardiovascular death by 28% compared with placebo (hazard ratio 0.72; 95% confidence interval 0.64 to 0.82), with consistent benefits across diabetic and non-diabetic subgroups.[5][6]

Established Glomerular Filtration Rate Thresholds: Evidence and Current Recommendations

The determination of appropriate estimated glomerular filtration rate thresholds for SGLT2 inhibitor initiation in non-diabetic chronic kidney disease has evolved substantially as evidence has accumulated, with contemporary recommendations extending therapy to substantially lower levels of renal function than initial trial entry criteria might have suggested. The DAPA-CKD trial enrolled patients with eGFR between 25 and 75 mL/min per 1.73 m², establishing that patients with stage 4 chronic kidney disease (eGFR 15 to 29 mL/min per 1.73 m²) constituted 14% of enrolled participants (624 of 4304 patients) with baseline eGFR 25 to 30 mL/min per 1.73 m², and prespecified subgroup analysis demonstrated a 27% reduction in the primary composite endpoint of sustained 50% eGFR decline, end-stage kidney disease, or kidney or cardiovascular death in this advanced chronic kidney disease population.[4][7] This finding was particularly significant because it demonstrated that SGLT2 inhibitor benefits extend to patients with severely reduced renal function, an observation that carried important implications for establishing minimum eGFR thresholds below which therapy should not be initiated. The EMPA-KIDNEY trial extended evidence to even more advanced stages of chronic kidney disease by enrolling 78% of participants with eGFR less than 45 mL/min per 1.73 m², and particularly importantly, including 2282 participants (approximately 35% of the total enrolled population) with advanced chronic kidney disease and eGFR between 20 and 30 mL/min per 1.73 m² at baseline.[5][6] The trial demonstrated that the kidney-protective effects of empagliflozin were maintained in patients with stage 4 chronic kidney disease (eGFR 20 to 30 mL/min per 1.73 m²), finally confirming that even patients with advanced chronic kidney disease benefit from SGLT2 inhibition.[2]

These robust trial-level findings have translated into contemporary clinical practice guidelines that now recommend SGLT2 inhibitor initiation at substantially lower eGFR thresholds than previously considered appropriate. The 2024 Kidney Disease: Improving Global Outcomes clinical practice guideline for chronic kidney disease evaluation and management provides a strong recommendation (1A evidence grade) for SGLT2 inhibitor use in adults with eGFR of 20 mL/min per 1.73 m² or higher who have either type 2 diabetes mellitus or heart failure, or who have urinary albumin-to-creatinine ratio of 200 mg/g or greater, irrespective of diabetes status.[8][9][10] The American Diabetes Association standards of care recommend that for people with type 2 diabetes and chronic kidney disease, use of a sodium-glucose cotransporter 2 inhibitor with demonstrated benefit is recommended to reduce chronic kidney disease progression and cardiovascular events in individuals with eGFR as low as 20 mL/min per 1.73 m².[11][12] This represents a substantial downward revision from previous recommendations that suggested an eGFR threshold of 25 mL/min per 1.73 m², reflecting the accumulating evidence from subgroup analyses that demonstrated maintained efficacy and safety at lower eGFR levels. The rationale for lowering the eGFR threshold to 20 mL/min per 1.73 m² is supported by prespecified and post-hoc subgroup analyses from DAPA-CKD and the overall trial design of EMPA-KIDNEY, which included patients with eGFR as low as 20 mL/min per 1.73 m², demonstrating comparable safety profiles and kidney protection across these lower eGFR ranges.[4][13]

Importantly, current guidelines emphasize that SGLT2 inhibitors may be continued until patients require kidney replacement therapy, even if eGFR declines below the 20 mL/min per 1.73 m² initiation threshold.[9][10] This distinction reflects recognition that the hemodynamic effects of SGLT2 inhibition—primarily reduction in glomerular hypertension and tubuloglomerular feedback—persist across the continuum of renal function decline, and that the benefits observed in trials with baseline eGFR greater than or equal to 20 mL/min per 1.73 m² likely extend to populations with more severe renal impairment. The clinical implication is that practitioners should not discontinue SGLT2 inhibitors in non-diabetic chronic kidney disease patients solely because eGFR falls below the 20 mL/min per 1.73 m² initiation threshold during long-term therapy, provided there are no contraindications such as development of diabetic ketoacidosis or hemodynamic instability. Additionally, it is crucial to recognize that glucose-lowering efficacy of SGLT2 inhibitors diminishes significantly as eGFR declines, becoming attenuated at eGFR less than 60 mL/min per 1.73 m² and minimal when eGFR is less than 30 mL/min per 1.73 m².[4][7] However, this loss of glycemic effect is immaterial to non-diabetic chronic kidney disease populations, in whom the kidney and cardiovascular protective mechanisms of SGLT2 inhibition operate independently of glucose metabolism, and thus the diminished glucose-lowering capacity should not influence treatment decisions regarding SGLT2 inhibitor initiation or continuation in non-diabetic patients.

Albuminuria and Proteinuria Thresholds: From Macroalbuminuria to Non-Albuminuric Disease

The assessment of urinary albumin excretion represents a critical parameter in risk stratification for chronic kidney disease progression and serves as a traditional prerequisite for many kidney-protective medications including renin-angiotensin system inhibitors. Historically, SGLT2 inhibitor trials incorporated albuminuria thresholds into enrollment criteria, with DAPA-CKD requiring urinary albumin-to-creatinine ratio between 200 and 5000 mg/g (representing both macroalbuminuria and nephrotic-range proteinuria), and CREDENCE requiring urinary albumin-to-creatinine ratio greater than 300 mg/g (strictly macroalbuminuric range).[1][2][7] These criteria reflected the mechanistic hypothesis that SGLT2 inhibition primarily benefited patients with evidence of glomerular dysfunction manifested by albuminuria, and that the drug class primarily addressed conditions characterized by glomerular hyperfiltration and sodium retention. However, subsequent evidence has substantially challenged and refined these assumptions, demonstrating that SGLT2 inhibitor benefits extend across the full spectrum of albuminuria levels, including patients with completely normal urinary albumin excretion.

The EMPA-KIDNEY trial specifically designed its protocol to address this evidence gap by intentionally enrolling patients across a wider range of albuminuria levels, including both those with eGFR greater than or equal to 45 but less than 90 mL/min per 1.73 m² (without requirement for increased albuminuria) and those with eGFR between 20 and less than 45 mL/min per 1.73 m² (with urinary albumin-to-creatinine ratio ≥200 mg/g).[5][6] The trial enrolled 3192 patients (48.3%) with urinary albumin-to-creatinine ratio less than 300 mg/g, including 1328 participants with completely normal albuminuria (urinary albumin-to-creatinine ratio <30 mg/g), representing approximately 20% of the total enrolled population.[1][5][2] This deliberately inclusive design provided the first substantial evidence regarding SGLT2 inhibitor efficacy in truly non-albuminuric chronic kidney disease, addressing a critical evidence gap particularly relevant to non-diabetic populations, in which many disease etiologies may progress without significant proteinuria.

The results from EMPA-KIDNEY regarding non-albuminuric disease presented a nuanced and clinically important finding. While the hazard ratio for the primary endpoint of kidney disease progression or cardiovascular death showed a non-significant 1% increase in participants with completely normal albuminuria, the long-term eGFR slope analysis revealed that empagliflozin substantially attenuated eGFR decline across all albuminuria categories, including the normoalbuminuric group.[1][2] Specifically, in the cohort with normal albuminuria at baseline, the placebo arm demonstrated an annual eGFR slope decline of approximately 3.13 mL/min per 1.73 m² per year, while the empagliflozin arm demonstrated an annual slope of approximately 2.75 mL/min per 1.73 m² per year, representing an attenuation of approximately 0.38 mL/min per 1.73 m² per year.[5] More substantially, in patients with urinary albumin-to-creatinine ratio between 30 and 300 mg/g (microalbuminuria), empagliflozin demonstrated substantial kidney protection with a 23% reduction in primary endpoint risk, while in patients with macroalbuminuria (urinary albumin-to-creatinine ratio >300 mg/g), the risk reduction was somewhat greater at 23%.[1][2] When considering the eGFR slope (annual rate of eGFR change) rather than clinical outcomes, the effect of SGLT2 inhibition was evident across all levels of urinary albumin-to-creatinine ratio, with absolute differences of 1.76 mL/min per 1.73 m² per year in patients with urinary albumin-to-creatinine ratio greater than 300 mg/g, 1.20 mL/min per 1.73 m² per year in those with urinary albumin-to-creatinine ratio between 30 and 300 mg/g, and 0.78 mL/min per 1.73 m² per year in those with normal albuminuria, all favoring empagliflozin.[1][2]

These observations have profound implications for SGLT2 inhibitor initiation thresholds in non-diabetic chronic kidney disease, suggesting that albuminuria status should not be the sole determinant of treatment eligibility. Current guideline recommendations reflect this evidence by recommending SGLT2 inhibitor use in non-diabetic chronic kidney disease patients with albuminuria levels ranging from normal to severely increased, specifically recommending use in patients with urinary albumin-to-creatinine ratio of 200 mg/g or greater as a strong indication, while providing conditional recommendations for use in patients with lower albuminuria or even those without albuminuria.[13][9][11] The 2024 Kidney Disease: Improving Global Outcomes guideline states that SGLT2 inhibitors are recommended in adults with eGFR of 20 mL/min per 1.73 m² or higher who have urinary albumin-to-creatinine ratio of 200 mg/g or greater, but also acknowledges that benefits extend to patients with lower albuminuria levels or completely normal albuminuria, particularly those with evidence of eGFR decline or other markers of kidney disease progression. For patients without albuminuria in non-diabetic chronic kidney disease, contemporary evidence supports SGLT2 inhibitor consideration based on other markers of kidney disease progression or high-risk eGFR and albuminuria combinations, such as those with preserved eGFR (≥45 mL/min per 1.73 m²) but evidence of prior eGFR loss or albuminuria development over time. Additionally, the presence of specific high-risk chronic kidney disease etiologies such as IgA nephropathy or focal segmental glomerulosclerosis may warrant SGLT2 inhibitor initiation at lower albuminuria thresholds or in the absence of albuminuria, recognizing that these glomerular diseases may present with relatively normal albuminuria despite progressive kidney dysfunction.

Disease Etiology Considerations and Subgroup-Specific Evidence

The remarkable diversity of non-diabetic chronic kidney disease etiologies necessitates nuanced consideration of how disease-specific pathophysiology might influence the efficacy and appropriateness of SGLT2 inhibitor therapy. Meta-analyses of chronic kidney disease trials have demonstrated that allocation to SGLT2 inhibitors conferred differential protection from chronic kidney disease progression depending on disease etiology, with 40% risk reduction in diabetic kidney disease, 30% in patients with ischemic or hypertensive kidney disease, 40% in patients with glomerulonephritis, and 26% in patients with chronic kidney disease of unknown etiology.[1][2] These variations, while generally favorable, suggest that disease-specific mechanisms may modulate the magnitude of SGLT2 inhibitor benefit, supporting the concept that the glomerular hyperfiltration and sodium retention mechanisms targeted by SGLT2 inhibitors may be more prominent in certain disease entities than others.

For primary glomerular diseases, particularly immunoglobulin A nephropathy and focal segmental glomerulosclerosis, subgroup analyses from both DAPA-CKD and EMPA-KIDNEY trials provide important evidence regarding SGLT2 inhibitor efficacy. In the DAPA-CKD trial, 229 patients had a diagnosis of IgA nephropathy and 97 had focal segmental glomerulosclerosis, representing approximately 10.6% and 2.3% of the trial population respectively.[1][2][7] Subgroup analysis revealed that dapagliflozin reduced proteinuria in these populations by approximately 26% in IgA nephropathy and comparably in focal segmental glomerulosclerosis, and importantly, dapagliflozin significantly attenuated eGFR decline in these glomerular disease populations.[1][2][7] Similarly, in EMPA-KIDNEY, participants with glomerular diseases experienced comparable kidney protection, with the trial enrolling more than 1600 participants with glomerular disease, representing approximately 24% of the total trial population, substantially more than in DAPA-CKD.[5] The subgroup analyses in EMPA-KIDNEY demonstrated that empagliflozin reduced the composite primary endpoint of kidney disease progression or cardiovascular death consistently in participants with various glomerular disease etiologies, suggesting that despite the mechanistic differences between immune-mediated glomerular diseases and the hyperfiltration-driven mechanism of diabetic kidney disease, SGLT2 inhibitors provide meaningful kidney protection across these diverse pathological entities. Critically, contemporary guidelines emphasize that SGLT2 inhibitor therapy should not be used as a substitute for immunosuppressive therapy when clinically indicated in inflammatory glomerular diseases, but rather as an adjunctive agent to reduce residual kidney disease progression.[7][44] This distinction is particularly important in non-diabetic chronic kidney disease populations where specific disease etiologies such as lupus nephritis, ANCA-associated vasculitis, and FSGS may require targeted immunosuppression as primary therapy, with SGLT2 inhibitors serving as supporting agents to modify the progression of chronic kidney damage.

For hypertensive kidney disease and ischemic nephropathy, SGLT2 inhibitor efficacy is substantial, with meta-analyses demonstrating a 30% relative risk reduction for chronic kidney disease progression.[1][2] This protection likely reflects the reduction in glomerular hypertension and improved renal hemodynamics that SGLT2 inhibitors achieve through reduction in tubuloglomerular feedback and changes in systemic hemodynamics. The mechanistic relevance to hypertensive kidney disease is particularly apparent, as these conditions are characterized by maladaptive glomerular hypertension in response to systemic hypertension, and SGLT2 inhibitor-mediated reduction in glomerular filtration rate and intraglomerular pressure directly addresses the pathophysiological substrate of disease progression. For tubulointerstitial diseases, which represented approximately 7% of the EMPA-KIDNEY trial population with greater than 450 enrolled participants, the mechanisms by which SGLT2 inhibitors provide kidney protection may differ from glomerular diseases, potentially involving reduction in tubular toxicity, attenuation of tubulointerstitial inflammation, and improved mitochondrial function in tubular epithelial cells.[3][5]

A particularly important consideration in non-diabetic chronic kidney disease concerns the potential body mass index dependency of SGLT2 inhibitor efficacy that has emerged from recent real-world data. A recent retrospective, multicentre, international observational cohort study of non-diabetic patients with biopsy-proven glomerular disease found that proteinuria reduction after SGLT2 inhibitor initiation was significant only in overweight and obese patients (P<0.001), with patients with normal body mass index (BMI <25 kg/m²) showing no significant proteinuria reduction and failing to experience the expected early decrease in eGFR.[14][15][16] Furthermore, a nationwide epidemiological study investigating kidney-protective effects of SGLT2 inhibitors in type 2 diabetic patients found that while SGLT2 inhibitors were associated with slower annual eGFR decline, their protective effects were significantly dependent on body mass index, with negligible effects in individuals with BMI less than 25.[17][50] This body mass index dependency is mechanistically coherent, as SGLT2 inhibitors primarily address sodium retention and volume expansion through natriuresis and osmotic diuresis, mechanisms that are most prominent in overweight and obese populations characterized by expanded extracellular fluid volume and sodium retention. In lean, non-diabetic chronic kidney disease patients, particularly those with early-stage disease whose disease progression is not linked to glomerular hyperfiltration or volume expansion but rather to immune-mediated inflammation, genetic dysregulation, or other non-hyperfiltration mechanisms, the efficacy of SGLT2 inhibitors may be substantially attenuated. This evidence suggests that SGLT2 inhibitor efficacy in non-diabetic chronic kidney disease may be condition-specific and patient-specific, requiring careful patient phenotyping and consideration of underlying disease mechanisms and physiological characteristics such as volume status and body composition.

The Initial eGFR Dip: Hemodynamic Efficacy and Clinical Interpretation

A critical and frequently misunderstood phenomenon associated with SGLT2 inhibitor initiation is the characteristic acute, reversible reduction in estimated glomerular filtration rate that occurs within one to four weeks of therapy initiation, often referred to as the eGFR "dip." Understanding this phenomenon and correctly interpreting its clinical significance is essential for clinicians managing non-diabetic chronic kidney disease patients, as misinterpretation of the eGFR dip as indicative of drug toxicity or acute kidney injury has historically led to inappropriate therapy discontinuation and loss of kidney-protective benefits. The magnitude of the eGFR dip varies across studies but generally falls within the range of 3 to 6 mL/min per 1.73 m², occurring typically within the first four weeks of therapy, with maximal decline generally apparent by two weeks.[4][18][19] In clinical trials, approximately 38% of patients treated with dapagliflozin experienced an eGFR decline of greater than 10% from baseline, with 13% experiencing declines greater than 20% and approximately 3.4% experiencing declines greater than 30%.[20][19] Importantly, this initial eGFR dip is similar in magnitude and character to the eGFR reduction observed with initiation of renin-angiotensin system blockade, reflecting comparable hemodynamic mechanisms of action.

The pathophysiological basis for the eGFR dip represents an important and favorable hemodynamic response rather than a sign of kidney injury. The primary mechanism by which SGLT2 inhibitors are thought to delay chronic kidney disease progression is through reduction in glomerular hyperfiltration and restoration of normal tubuloglomerular feedback regulation.[4][2][7] In chronic kidney disease, the kidneys operate under conditions of pathological glomerular hypertension and enhanced single-nephron glomerular filtration rate, representing a maladaptive compensatory response to nephron loss that paradoxically accelerates the deterioration of remaining renal function through progressive glomerular damage. SGLT2 inhibitors, through their effects on sodium reabsorption and glucose reabsorption in the proximal tubule, reduce sodium delivery to the macula densa and decrease intracellular ATP concentration, leading to restoration of tubuloglomerular feedback signaling and reduction in glomerular capillary hydrostatic pressure.[1][3] This reduction in intraglomerular hypertension is reflected acutely in a modest decrease in glomerular filtration rate, as the reduction in driving pressure for filtration decreases the filtered load of creatinine and thus the calculated eGFR. Crucially, this initial eGFR dip is associated with superior long-term kidney outcomes, as clinical trial data consistently demonstrate that patients experiencing larger initial eGFR declines have the best long-term eGFR trajectories, indicating that more substantial initial hemodynamic modulation predicts more robust kidney protection.[20][19]

The clinical data regarding safety of the eGFR dip are reassuring and should guide clinical decision-making. Post-hoc analyses from CREDENCE, EMPA-REG OUTCOME, and VERTIS-CV have examined the relationship between magnitude of initial eGFR decline and long-term renal outcomes, demonstrating that the long-term eGFR trajectories and kidney safety profiles were similar regardless of the magnitude of the initial eGFR dip.[20] In the CREDENCE trial, an initial eGFR dip greater than 30% was a rare event occurring in only 0.5% of canagliflozin-treated participants, and in this small subgroup the risk for kidney-related adverse events was only slightly increased compared with nondippers.[20][19] Importantly, meta-analyses have conclusively demonstrated that SGLT2 inhibitors do not cause acute kidney injury and in fact may even reduce the likelihood of acute kidney injury occurring.[20][19] These findings have led to contemporary guideline recommendations that initial eGFR declines of less than 30% should be tolerated and should not prompt therapy discontinuation.[4][18][10] For patients experiencing initial eGFR declines exceeding 30%, evaluation for contributing factors such as volume depletion, concurrent initiation of additional hemodynamically active agents, or unrecognized acute kidney injury from other causes is appropriate, but the SGLT2 inhibitor should generally be continued if the eGFR decline appears to be purely hemodynamic in nature without other evidence of kidney injury. Guidelines suggest that in the circumstance of an eGFR decline greater than 30%, the SGLT2 inhibitor may be temporarily withheld to allow eGFR recovery toward baseline, at which point therapy can be re-initiated with more gradual titration or dose reduction if appropriate.[4]

The clinical implication is that practitioners should reassure non-diabetic chronic kidney disease patients regarding the expected eGFR dip and specifically should not discontinue therapy or adjust other medications in response to this anticipated hemodynamic effect. Additionally, routine monitoring of serum creatinine immediately after SGLT2 inhibitor initiation is not necessary in most patients, as the eGFR dip represents a predictable and benign phenomenon that should not alter clinical management decisions. For high-risk patients including those with baseline blood pressure less than 120/70 mm Hg, those on high-dose loop diuretics, those with orthostatic symptoms, or those with recent acute kidney injury, it is reasonable to obtain renal function assessment approximately one month after SGLT2 inhibitor initiation to confirm that any eGFR decline falls within expected ranges and does not exceed 30% or is not associated with other evidence of acute kidney injury.

Clinical Decision-Making Framework: Integration of Thresholds with Patient Phenotype

The contemporary evidence regarding SGLT2 inhibitor thresholds for non-diabetic chronic kidney disease supports a clinical decision-making framework that integrates estimated glomerular filtration rate, albuminuria levels, disease etiology, and individual patient characteristics rather than rigid, categorical thresholds. The core principle underlying current recommendations is that SGLT2 inhibitors should be considered for essentially all non-diabetic chronic kidney disease patients with eGFR of 20 mL/min per 1.73 m² or higher, with specific strong recommendations for those with urinary albumin-to-creatinine ratio of 200 mg/g or greater, and with reasonable consideration in those with lower albuminuria or even those without albuminuria if there is evidence of prior eGFR loss or other markers of high-risk chronic kidney disease. The decision to initiate SGLT2 inhibitors should incorporate assessment of disease etiology, volume status, blood pressure control, concurrent medications, and individual patient characteristics including body mass index, age, and presence of heart failure or cardiovascular disease.

For non-diabetic chronic kidney disease patients presenting with eGFR between 20 and 44 mL/min per 1.73 m² and albuminuria (urinary albumin-to-creatinine ratio ≥200 mg/g), SGLT2 inhibitor initiation represents a strong recommendation with unequivocal evidence support from landmark trials demonstrating both safety and efficacy in this population.[1][4][9] For non-diabetic chronic kidney disease patients with eGFR between 45 and 89 mL/min per 1.73 m² and albuminuria (urinary albumin-to-creatinine ratio ≥200 mg/g), SGLT2 inhibitors are recommended, with particularly strong evidence in those with more advanced albuminuria or evidence of prior eGFR decline.[5][9] For non-diabetic chronic kidney disease patients with preserved eGFR (≥90 mL/min per 1.73 m²) but macroalbuminuria (urinary albumin-to-creatinine ratio >300 mg/g) or other evidence of high-risk chronic kidney disease, SGLT2 inhibitors may be considered, although evidence is more limited in this population. For non-diabetic chronic kidney disease patients with eGFR ≥45 mL/min per 1.73 m² and lower albuminuria levels (urinary albumin-to-creatinine ratio 30-200 mg/g) or even those without albuminuria, the decision to initiate SGLT2 inhibitors should incorporate assessment of disease etiology, volume status, presence of heart failure, and individual patient factors, with the recognition that benefits extend across these lower albuminuria ranges but that the magnitude of benefit may be somewhat attenuated in truly non-albuminuric disease compared to those with albuminuria. For non-diabetic chronic kidney disease patients with specific high-risk etiologies such as IgA nephropathy or focal segmental glomerulosclerosis, SGLT2 inhibitor consideration may be warranted at lower albuminuria thresholds or without significant albuminuria, recognizing that these glomerular diseases warrant aggressive kidney protection and that SGLT2 inhibitors have demonstrated efficacy in reducing proteinuria and slowing eGFR decline in these populations even in the absence of diabetes.

Special Population Considerations: Body Mass Index and Lean Patients

The emerging evidence regarding body mass index dependency of SGLT2 inhibitor efficacy in non-diabetic chronic kidney disease presents important considerations for patient selection and prognostication. The mechanistic basis for this BMI dependency relates to the primary site of SGLT2 action in the proximal tubule and the hemodynamic effects mediated through natriuresis and osmotic diuresis. In overweight and obese patients, who characteristically demonstrate enhanced sodium retention, volume expansion, and glomerular hyperfiltration as compensatory responses to these abnormalities, SGLT2 inhibitor-mediated natriuresis and reduction in glomerular hypertension may be particularly impactful. In lean, non-diabetic chronic kidney disease patients, particularly those with early-stage disease, the disease progression may be primarily driven by mechanisms unrelated to hyperfiltration or sodium retention, such as immune-mediated inflammation in glomerulonephritis, genetic dysregulation in Alport syndrome, or other non-hemodynamic pathological processes. In these populations, the efficacy of SGLT2 inhibitors may be limited, as the drug class does not directly address the primary pathogenic mechanisms underlying disease progression. This consideration should inform clinical discussions with lean non-diabetic chronic kidney disease patients regarding SGLT2 inhibitor use, with practitioners explaining that while SGLT2 inhibitors are recommended for patients meeting eGFR and albuminuria thresholds, the magnitude of benefit may be more modest in lean individuals compared to overweight or obese patients.

Contemporary practice should incorporate assessment of body mass index and volume status when considering SGLT2 inhibitor initiation in non-diabetic chronic kidney disease. For overweight and obese patients (BMI ≥25 kg/m²), SGLT2 inhibitor initiation represents a particularly strong recommendation, with expectation of meaningful proteinuria reduction and eGFR slope attenuation. For lean patients (BMI <25 kg/m²), SGLT2 inhibitor initiation may still be appropriate based on eGFR and albuminuria criteria and the strength of overall evidence, but clinical discussions should acknowledge the possibility that kidney protective effects may be more modest than in higher BMI populations. Additionally, assessment of volume status and sodium handling should inform SGLT2 inhibitor use, with therapy being particularly appropriate in patients with evidence of volume expansion, edema, or sodium retention, while practitioners should exercise caution in volume-depleted or euvolemic lean patients where additional natriuresis might precipitate hemodynamic compromise.

Adverse Effects and Safety Considerations Relevant to Threshold Setting

The safety profile of SGLT2 inhibitors represents an important consideration in threshold-setting decisions, as certain adverse effects may be more prevalent at lower eGFR levels or may necessitate modified approaches to therapy initiation. The major adverse effects associated with SGLT2 inhibitors include genital and urinary tract infections, volume depletion with potential acute kidney injury in susceptible populations, diabetic ketoacidosis particularly in lean patients or those on low-carbohydrate diets, bone fractures, and rare events such as Fournier's gangrene and lower extremity amputations.[21][22][46]``[48] Of these adverse effects, genital infections represent the most common, occurring with a 2- to 4-fold increased risk compared to placebo, with the highest incidence observed in the first two weeks after SGLT2 inhibitor initiation.[22][44] Genital infections are more common in women and those with prior history of genital infections, suggesting that patient counseling regarding hygiene and early recognition of symptoms is warranted. The risk of urinary tract infections with SGLT2 inhibitors has been controversial, with earlier observational reports suggesting increased risk, but subsequent randomized controlled trials demonstrating no increased risk of uncomplicated urinary tract infections.[44]``[53] However, in patients with history of complicated urinary tract infections including those with chronic indwelling catheters, SGLT2 inhibitors should be used with caution.

The risk of volume depletion and acute kidney injury with SGLT2 inhibitors is particularly relevant to threshold-setting considerations, as patients with lower baseline eGFR may be more susceptible to hemodynamic compromise from the natriuretic effects of these drugs. Volume depletion risk is substantially heightened in patients concurrently taking loop or thiazide diuretics, those with baseline blood pressure less than 120/70 mm Hg, those with orthostatic symptoms, elderly patients, and those experiencing acute illness with nausea and vomiting.[4][44]``[47] For non-diabetic chronic kidney disease patients being considered for SGLT2 inhibitor therapy, assessment of volume status prior to initiation is appropriate, and consideration should be given to reducing concurrent diuretic doses if the patient is not volume-overloaded at baseline. Guidelines recommend providing patients with sick-day advice regarding temporary discontinuation of SGLT2 inhibitors during acute illness with nausea, vomiting, or diarrhea, and practitioners should ensure patients understand symptoms of volume depletion including lightheadedness, orthostatic symptoms, or excessive fatigue.

The risk of diabetic ketoacidosis (DKA) with SGLT2 inhibitors, while rare with an estimated incidence of 3-4 cases per 10,000 person-years, carries important implications for patient selection and counseling.[22][46] The risk is higher in patients with low body mass index, those on low-carbohydrate or ketogenic diets, those with pancreatic insufficiency, those with history of prior DKA, and patients undergoing surgery or prolonged fasting.[46]``[48] The mechanism of SGLT2 inhibitor-associated DKA involves reduction in insulin secretion due to glucose lowering, increased glucagon secretion, increased hepatic ketone production, and decreased renal ketone clearance. Importantly, SGLT2 inhibitor-associated DKA may present with euglycemia (normal or only mildly elevated glucose), which can delay diagnosis if clinicians are not vigilant.[46] For non-diabetic chronic kidney disease patients, the DKA risk is substantially lower than in diabetic populations due to absence of the insulin deficiency characteristic of diabetes, but isolated case reports of euglycemic DKA in non-diabetic patients on SGLT2 inhibitors warrant mentioning this rare risk during patient counseling. Patients should be advised to avoid ketogenic diets while on SGLT2 inhibitors, to report symptoms of nausea, vomiting, abdominal pain, or unusual fatigue, and to undergo ketone level measurement if unwell even in the absence of hyperglycemia.

Integration of Threshold Decisions with Combination Therapy Strategies

Contemporary management of non-diabetic chronic kidney disease increasingly emphasizes combination therapy addressing multiple pathophysiological pathways, with SGLT2 inhibitors forming a foundational component of such approaches. For non-diabetic chronic kidney disease patients meeting threshold criteria for SGLT2 inhibitor initiation, concurrent optimization of renin-angiotensin system blockade with maximally tolerated doses of ACE inhibitors or angiotensin receptor blockers represents a prerequisite, as all landmark trials incorporated background renin-angiotensin system blockade as a standard of care component. The combination of renin-angiotensin system blockade and SGLT2 inhibition provides synergistic kidney protection through complementary mechanisms, with trial-level estimates from DAPA-CKD demonstrating that for a 50-year-old patient with non-diabetic chronic kidney disease and albuminuria, the combination of renin-angiotensin system blockade and SGLT2 inhibition provided a 7.4-year gain in kidney-failure-free survival compared to no treatment.[1][23] For patients with persistent albuminuria despite optimized renin-angiotensin system blockade and SGLT2 inhibition, consideration of additional agents including non-steroidal mineralocorticoid receptor antagonists (such as finerenone) or glucagon-like peptide-1 receptor agonists (in those with concomitant obesity) may provide additional albuminuria reduction and kidney protection.

The interrelationships between these agents should inform the decision regarding SGLT2 inhibitor thresholds, with recognition that benefit accrues not simply from meeting category-based thresholds but from achieving comprehensive multifactorial kidney disease management. For non-diabetic chronic kidney disease patients with eGFR in the range where renin-angiotensin system blockade alone is being considered, the addition of SGLT2 inhibitors at threshold eGFR levels (≥20 mL/min per 1.73 m²) provides incremental benefit beyond renin-angiotensin system blockade alone, justifying their routine addition to therapeutic regimens. For patients with advanced chronic kidney disease (eGFR <30 mL/min per 1.73 m²), the decision to continue renin-angiotensin system blockade and SGLT2 inhibitors must be carefully balanced against risks of hyperkalemia and volume depletion, with closer monitoring of serum potassium and blood pressure at baseline and one month after any medication adjustments.

Monitoring and Follow-Up Considerations Following Threshold-Based Initiation

Once the determination has been made to initiate SGLT2 inhibitors in non-diabetic chronic kidney disease patients meeting eGFR and albuminuria threshold criteria, appropriate monitoring protocols should be implemented to ensure therapy tolerability and detect any early complications. Initial counseling should address the anticipated eGFR dip, expected effects on urinary glucose and frequency of urination, and signs and symptoms requiring urgent medical attention including severe orthostatic symptoms, persistent nausea or vomiting, or signs of genital infection. Baseline assessment should include measurement of serum creatinine and eGFR, serum potassium (particularly important in patients with eGFR <30 mL/min per 1.73 m² or those on concurrent renin-angiotensin system blockade), blood pressure measurement, and documentation of current diuretic therapy. Following SGLT2 inhibitor initiation, assessment of renal function at approximately four to eight weeks is reasonable for high-risk patients including those with baseline eGFR <30 mL/min per 1.73 m², those with recent acute kidney injury history, those on high-dose loop diuretics, or those with systolic blood pressure <120 mm Hg. For lower-risk patients with baseline eGFR ≥30 mL/min per 1.73 m², euvolemia, and stable blood pressure, routine assessment of renal function at the next scheduled clinic visit (generally 3-6 months after initiation) is appropriate and sufficient.

Serum potassium monitoring warrants specific attention in non-diabetic chronic kidney disease patients on SGLT2 inhibitors, as the interplay between SGLT2 inhibitor effects on potassium excretion and concurrent renin-angiotensin system blockade necessitates careful vigilance. SGLT2 inhibitors increase distal tubular sodium delivery and promote urine flow rate, both of which enhance renal potassium excretion and tend to lower serum potassium levels or prevent hyperkalemia.[4][18] This effect appears particularly valuable in patients with advanced chronic kidney disease at risk for hyperkalemia due to reduced glomerular filtration rate. However, clinical decisions regarding potassium monitoring should be individualized based on baseline renal function and concurrent medications. Guidelines suggest that potassium levels do not routinely require assessment immediately after SGLT2 inhibitor initiation in patients without advanced chronic kidney disease or other risk factors for dyskalemia, but that assessment should be obtained in patients with baseline eGFR <30 mL/min per 1.73 m², those on concurrent mineralocorticoid receptor antagonists or potassium-sparing diuretics, or those with baseline hyperkalemia.[4][9]

Conclusion: Evidence-Based Framework for SGLT2 Inhibitor Thresholds in Non-Diabetic CKD

The contemporary evidence supporting sodium-glucose cotransporter-2 inhibitor use in non-diabetic chronic kidney disease establishes clear evidence-based thresholds for therapy initiation, with current recommendations supporting SGLT2 inhibitor use in essentially all non-diabetic chronic kidney disease patients with estimated glomerular filtration rate of 20 mL/min per 1.73 m² or higher, regardless of albuminuria status.[1][4][13][2][9][10] The magnitude of evidence supporting these thresholds derives from landmark randomized controlled trials including DAPA-CKD and EMPA-KIDNEY that deliberately enrolled substantial numbers of non-diabetic participants and demonstrated consistent kidney-protective benefits across diverse chronic kidney disease etiologies, albuminuria levels, and stages of renal function. The decision to initiate SGLT2 inhibitors in individual non-diabetic chronic kidney disease patients should incorporate specific attention to the patient's renal function (targeting eGFR ≥20 mL/min per 1.73 m²), urinary albumin excretion (with strong recommendations for urinary albumin-to-creatinine ratio ≥200 mg/g, and reasonable consideration for lower albuminuria or normoalbuminuric disease), disease etiology and pathophysiology, volume status and blood pressure, body mass index, and presence of heart failure or cardiovascular disease. Clinicians should counsel patients regarding the anticipated and benign hemodynamic eGFR dip that occurs with SGLT2 inhibitor initiation, should not discontinue therapy in response to eGFR declines <30%, and should implement monitoring protocols appropriate to individual patient risk profiles. The integration of SGLT2 inhibitors into comprehensive non-diabetic chronic kidney disease management incorporating optimized renin-angiotensin system blockade and potentially additional agents such as non-steroidal mineralocorticoid receptor antagonists represents the contemporary standard of care for achieving maximal kidney and cardiovascular protection.


Key Related Clinical Questions for Further Consideration

  1. How should SGLT2 inhibitor therapy be managed in non-diabetic chronic kidney disease patients who develop acute kidney injury or volume depletion during treatment initiation? This question addresses the critical clinical scenario of apparent adverse drug effect and requires understanding of when temporary therapy discontinuation is appropriate versus when therapy continuation with supportive measures is warranted.

  2. What is the comparative efficacy and safety of different SGLT2 inhibitors in non-diabetic chronic kidney disease, and do specific agents demonstrate superiority in particular disease etiologies or patient subgroups? This question reflects the practical clinical reality that multiple SGLT2 inhibitors are available with slightly different pharmacokinetic and pharmacodynamic properties, and clinicians must make informed choices regarding agent selection.

  3. What is the role of SGLT2 inhibitors in non-diabetic chronic kidney disease patients with preserved ejection fraction heart failure or those with advanced chronic kidney disease stage 4 disease approaching dialysis dependency? This question addresses emerging indications and populations for whom trial evidence is limited but clinical rationale for therapy is compelling.

Fuentes

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC9953060/
  2. https://www.ncbi.nlm.nih.gov/books/NBK576405/
  3. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1574693/full
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9263228/
  5. https://academic.oup.com/ckj/article/16/8/1187/7199787
  6. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2024-CKD-Guideline-Executive-Summary.pdf
  7. https://pace-cme.org/news/fda-approves-sglt2-inhibitor-for-ckd/2456532/
  8. https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC12189458/
  10. https://www.nature.com/articles/s41598-025-86172-y
  11. https://academic.oup.com/ckj/article/17/8/sfae100/7640869
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC7924151/
  13. https://diabetesjournals.org/care/article/45/9/2182/147052/Addendum-11-Chronic-Kidney-Disease-and-Risk
  14. https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfaf197/8263928
  15. https://diabetesjournals.org/care/article/48/Supplement_1/S239/157554/11-Chronic-Kidney-Disease-and-Risk-Management
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC9718016/
  17. https://academic.oup.com/ndt/article/40/10/1838/8063570
  18. https://www.ahajournals.org/doi/10.1161/JAHA.123.033236
  19. https://www.ukkidney.org/sites/renal.org/files/UKKA%20guideline_SGLT2i%20in%20adults%20with%20kidney%20disease%20v1%2020.10.21.pdf
  20. https://academic.oup.com/ndt/article/40/Supplement_1/i59/8002192
  21. https://clinicaltrials.gov/study/NCT03036150
  22. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/fda-accepts-new-chronic-kidney-disease-treatment-application
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC12259609/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC9217655/
  25. https://www.revistanefrologia.com/en-recommendations-for-evaluation-treatment-patients-avance-S2013251425001361
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC9871839/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8455037/
  28. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.058910
  29. https://diabetesjournals.org/care/article/47/Supplement_1/S219/153938/11-Chronic-Kidney-Disease-and-Risk-Management
  30. https://www.droracle.ai/articles/504769/what-is-the-best-initial-treatment-to-add-angiotensin-converting
  31. https://jamanetwork.com/journals/jamacardiology/fullarticle/2806257
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC9075441/
  33. https://kdigo.org/wp-content/uploads/2024/07/07232024-KDIGO-CKD.pdf
  34. https://anzsnevents.com/wp-content/uploads/2023/10/ANZSN-UC_2023-Muh-Geot-Wong.pdf
  35. https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.1010693/full
  36. https://my.clevelandclinic.org/health/treatments/sglt2-inhibitors
  37. https://www.ccjm.org/content/91/7/415
  38. https://www.kidney.org/kidney-topics/sglt2-inhibitors
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC12477470/
  40. https://pubmed.ncbi.nlm.nih.gov/38680053/
  41. https://www.acc.org/CVDinDMClinicianTool
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC11194332/
  43. https://www.droracle.ai/articles/152276/dosage-of-sglt2i

Respuesta generada por inteligencia artificial a partir de las fuentes citadas. Verifica las fuentes antes de aplicarla.

¿Tienes una pregunta sobre tu propio caso? Itaca responde con fuentes en segundos.

Hacer una pregunta

Más preguntas sobre enfermedad renal crónica